Literature DB >> 24992549

Avoidance of nonsteroidal anti-inflammatory drugs after negative provocation tests in urticaria/angioedema reactions: Real-world experience.

Luisa Bommarito1, Giuliana Zisa, Francesca Riccobono, Elisa Villa, Cristian D'Antonio, Ambra M Calamari, Mariangela Poppa, Adele Moschella, Carlo Di Pietrantonj, Maurizio Galimberti.   

Abstract

Drug provocation tests (DPTs) are the gold standard in diagnosing nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity; however, only few data about follow-up of patients with negative DPTs are actually available. The aim of this study was to assess patients' behavior in taking NSAIDs again and to evaluate NSAID tolerability after negative allergological workup. This is a follow-up study involving patients evaluated for history of cutaneous reactions (urticaria and or angioedema) after NSAID intake and with negative DPTs with the suspected NSAID. Patients were asked during a phone interview about the intake of NSAIDs, tolerance, or reasons of avoidance. The negative predictive value (NPV) of NSAIDs DPTs was calculated. One hundred eleven of 142 patients were successfully contacted; 46/111 (41.44%) took the same NSAID previously tested with two adverse reactions reported (4.34%). Fifty-three of 111 (47.74%) patients did not take the same NSAID, but 34 of them took at least another strong cyclooxygenase (COX) 1 inhibitor, with 1 adverse reaction (2.94%) and 19 of them took only weak COX-1 inhibitors. Twelve of 111 patients (10.8%) did not take any NSAID. Reasons for drug avoidance were mainly fear of reactions (70.8%) and no need (29.2%). NPV, overall, was 96.97% (95% confidence interval, 91-99%). Although NSAID hypersensitivity diagnosis was ruled out by oral provocation test, the majority of patients with a history of urticaria/angioedema avoided the intake of the tested NSAIDs for fear of new reactions, particularly when strong COX-1 inhibitor NSAIDs were involved. The high NPV value of DPT resulting from this study should reassure NSAID intake.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24992549     DOI: 10.2500/aap.2014.35.3765

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  3 in total

1.  Insights, strategies, asthma and allergy risk factors, and the allergist/immunologist: Challenges to be met and promises to keep!

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2016 Jan-Feb       Impact factor: 2.587

2.  Allergic rhinitis: From discernment of symptoms to implementation of new therapeutic modalities.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2014 Jul-Aug       Impact factor: 2.587

Review 3.  Pro and Contra: Provocation Tests in Drug Hypersensitivity.

Authors:  Ozge Soyer; Umit Murat Sahiner; Bulent Enis Sekerel
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.